IP Library Granted Patent US 10,457,740
Granted Patent B1
US 10,457,740 · App. 16/140,151 · Granted Oct 29, 2019

Methods and compositions for treating cancer using P2RX2 inhibitors

Inventors: Avak Kahvejian (Lexington, MA); Jordi Mata-Fink (Baltimore, MD); Jonathan Barry Hurov (Bedford, MA); Alexandra Lantermann (Boston, MA)
Assignee: Flagship Pioneering Innovations V, Inc.
C07K16/303A61P35/00C07K2317/54C07K2317/565C07K2317/72C07K2317/75C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,457,740
App. No.
16/140,151
Granted
Oct 29, 2019
Kind
B1
Abstract

The present invention provides methods for treating cancer using P2RX2 inhibitors, such as P2RX2 inhibitory antibodies, among others. The invention also features compositions containing P2RX2 inhibitors, methods of diagnosing patients with P2RX2-associated cancer, and methods of predicting the response of cancer in a subject to treatment with P2RX2 inhibitors.

Claims (1)

1. A method of treating a human subject identified as having pancreatic cancer, the method comprising administering to the subject an amount of a small molecule P2RX2 antagonist effective to reduce growth of the pancreatic cancer, thereby treating the subject, wherein the small molecule P2RX2 antagonist is selected from the group consisting of CHEMBL494161, CHEMBL119416, CHEMBL604158, CHEMBL1672098, CHEMBL495204, CHEMBL 499580, CHEMBL598857, CHEMBL1671997, CHEMBL523173, CHEMBL1672107, CHEMBL597820, CHEMBL1671996, CHEMBL492300, CHEMBL523043, CHEMBL597591, CHEMBL1671993, CHEMBL494159, CHEMBL521983, CHEMBL597203, CHEMBL1671992, CHEMBL494353, CHEMBL500550, CHEMBL596982, CHEMBL134193, CHEMBL494160, CHEMBL492299, CHEMBL524284, CHEMBL133576, CHEMBL494158, CHEMBL504607, CHEMBL524064, CHEMBL131271, CHEMBL526307, CHEMBL494176, CHEMBL522725, CHEMBL118007, CHEMBL492934, CHEMBL493547, CHEMBL522053, CHEMBL116926, CHEMBL492933, CHEMBL493546, CHEMBL521709, CHEMBL492729, CHEMBL494582, CHEMBL446310, CHEMBL499428, CHEMBL521820, CHEMBL492907, CHEMBL69727, CHEMBL498038, CHEMBL494940, CHEMBL492703, CHEMBL331358, CHEMBL496229, CHEMBL492789, CHEMBL1672104, CHEMBL494833, CHEMBL496022, CHEMBL69234, CHEMBL495203, CHEMBL509572, CHEMBL495834, CHEMBL401735, CHEMBL1672105, CHEMBL496030, CHEMBL495796, CHEMBL494834, CHEMBL448525, CHEMBL1671995, CHEMBL450832, CHEMBL494832, CHEMBL271672, CHEMBL523000, CHEMBL404659, CHEMBL494772, CHEMBL496401, CHEMBL492968, CHEMBL404450, CHEMBL494181, CHEMBL413145, CHEMBL271688, CHEMBL403051, CHEMBL257495, CHEMBL119180, CHEMBL494581, CHEMBL402239, CHEMBL117766, CHEMBL502618, CHEMBL45413, CHEMBL256864, CHEMBL495195, CHEMBL444469, CHEMBL331250, CHEMBL256688, CHEMBL493740, CHEMBL1672106, CHEMBL492967, CHEMBL256057, CHEMBL492562, CHEMBL493741, CHEMBL492744, CHEMBL1672103, CHEMBL477339, CHEMBL443930, CHEMBL606414, CHEMBL1672102, CHEMBL492935, CHEMBL604300, CHEMBL1672099, CHEMBL522184, and CHEMBL492745.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2018
From: KAHVEJIAN, AVAK; MATA-FINK, JORDI
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 047293/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2018
From: HUROV, JONATHAN BARRY; LANTERMANN, ALEXANDRA
To: CYGNAL THERAPEUTICS, INC.
Reel/Frame 047293/0313 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2018
From: CYGNAL THERAPEUTICS, INC.
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 047293/0441 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2018
From: FLAGSHIP PIONEERING, INC.
To: FLAGSHIP PIONEERING INNOVATIONS V, INC.
Reel/Frame 047294/0130 →
Continuity (1)
Provisional Application 62623236 · Jan 29, 2018
Cited By (2)
US 12,365,665 US 12,600,787